NASDAQ:ILMN - Illumina Stock Price, Forecast & News

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings data on Thursday, October, 24th. The life sciences company reported $1.93 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.40 by $0.53. The life sciences company had revenue of $907 million for the quarter, compared to analysts' expectations of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The business's quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.52 EPS. View Illumina's Earnings History.

Illumina is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Illumina.

Illumina updated its FY19 earnings guidance on Thursday, October, 24th. The company provided earnings per share (EPS) guidance of $6.40-6.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.04.

14 analysts have issued 1-year price objectives for Illumina's stock. Their forecasts range from $280.00 to $380.00. On average, they anticipate Illumina's stock price to reach $331.85 in the next year. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for Illumina.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.

Media coverage about ILMN stock has trended very negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Illumina earned a news impact score of -3.7 on InfoTrie's scale. They also gave news headlines about the life sciences company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Illumina.

Illumina saw a increase in short interest in November. As of November 15th, there was short interest totalling 3,750,000 shares, an increase of 7.4% from the October 31st total of 3,490,000 shares. Based on an average trading volume of 999,400 shares, the days-to-cover ratio is currently 3.8 days. Currently, 2.6% of the shares of the stock are short sold. View Illumina's Current Options Chain.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Visa (v), Baidu (BIDU), Walt Disney (DIS), Adobe (ADBE), Gilead Sciences (GILD), Paypal (PYPL) and salesforce.com (CRM).

Illumina's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.89%), Nikko Asset Management Americas Inc. (0.51%), Massachusetts Financial Services Co. MA (0.47%), Chevy Chase Trust Holdings Inc. (0.33%), Voya Investment Management LLC (0.32%) and WCM Investment Management LLC (0.29%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein and Sam Samad. View Institutional Ownership Trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Stifel Financial Corp, State of Michigan Retirement System, Robeco Institutional Asset Management B.V., Stephens Investment Management Group LLC, Castleark Management LLC and Gabelli Funds LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein and Sam Samad. View Insider Buying and Selling for Illumina.

ILMN stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., California Public Employees Retirement System, Voya Investment Management LLC, Massachusetts Financial Services Co. MA, Parnassus Investments CA, Ardevora Asset Management LLP and WCM Investment Management LLC. View Insider Buying and Selling for Illumina.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ILMN stock can currently be purchased for approximately $326.47.

Illumina has a market capitalization of $47.99 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina.

The official website for Illumina is http://www.illumina.com/.

Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]